BESREMI DIN 02569728
Health Canada record
| Active ingredient(s) | ROPEGINTERFERON ALFA-2B 500 MCG |
|---|---|
| Dosage form | Solution |
| Route | Subcutaneous |
| Schedule | PRESCRIPTION; SCHEDULE D |
| Class | Human |
| ATC | L03AB15 ROPEGINTERFERON ALFA-2B |
| Original market date | |
| Current status date | 02-Jul-2026 |
| Source | Health Canada DPD |
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 37818 | 2026-07-02 | New Drug Submission (NDS) |